Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Kaiser Permanente Center for Effectiveness & Safety Research, Pasadena, CA, USA.
J Bone Miner Res. 2018 Jul;33(7):1252-1259. doi: 10.1002/jbmr.3420. Epub 2018 May 24.
Holidays from bisphosphonates (BPs) may help to prevent rare adverse events such as atypical femoral fractures, but may be appropriate only if risk of osteoporosis-related fractures does not increase. Our objective was to compare the incidence of osteoporosis-related fractures among women who had a BP holiday to those who continued to use BPs. This retrospective cohort study, conducted within four Kaiser Permanente integrated health system regions, included 39,502 women aged ≥45 years with ≥3 years exposure to BP. Participants with a BP holiday (≥12 months with no use) were compared to persistent (use with ≥50% adherence) and nonpersistent (use with <50% adherence) users for incident osteoporosis-related fractures. The BP holiday (n = 11,497), nonpersistent user (n = 10,882), and persistent user groups (n = 17,123) were observed for 156,657 person-years. A total of 5199 osteoporosis-related fractures (including 1515 hip fractures and 2147 vertebral fractures) were observed. Compared to the persistent use group, there was a slight difference in overall osteoporosis-related fracture risk (HR 0.92; 95% CI, 0.84 to 0.99)and no difference in hip fracture risk (HR 0.95; 95% CI, 0.83 to 1.10) for the BP holiday group. A slight reduction in risk of vertebral fracture was observed (HR 0.83; 95% CI, 0.74 to 0.95). Compared to the nonpersistent user group, the BP holiday group was at decreased risk for osteoporosis-related fractures (HR 0.71; 95% CI, 0.65 to 0.79), vertebral fractures (HR 0.68; 95% CI, 0.59 to 0.78), and hip fractures (HR 0.59; 95% CI, 0.50 to 0.70). Women who undertake a BP holiday from BP of ≥12 months duration for any reason after ≥3 years of BP use do not appear to be at greater risk of osteoporosis-related fragility fracture, hip, or vertebral fractures compared to ongoing BP users. In our cohort, BP holiday remains a viable strategy for balancing the benefits and potential harms associated with long-term BP use. © 2018 American Society for Bone and Mineral Research.
停用双膦酸盐(BPs)可能有助于预防罕见的不良事件,如非典型股骨骨折,但只有在骨质疏松性骨折风险不增加的情况下才是合适的。我们的目的是比较使用 BP 药物的女性中,有 BP 假期的患者与继续使用 BP 的患者之间与骨质疏松症相关的骨折发生率。这项回顾性队列研究在四个 Kaiser Permanente 综合医疗系统区域进行,共纳入 39502 名年龄≥45 岁且有≥3 年 BP 暴露史的女性。有 BP 假期(≥12 个月未使用)的患者与持续(≥50%的依从性使用)和非持续(<50%的依从性使用)的患者相比,评估其发生骨质疏松性骨折的情况。BP 假期(n=11497)、非持续使用(n=10882)和持续使用(n=17123)的观察时间为 156657 人年。共观察到 5199 例骨质疏松性骨折(包括 1515 例髋部骨折和 2147 例椎体骨折)。与持续使用组相比,BP 假期组的整体骨质疏松性骨折风险(HR 0.92;95%CI,0.84 至 0.99)略有差异,髋部骨折风险(HR 0.95;95%CI,0.83 至 1.10)无差异。椎体骨折风险观察到轻微降低(HR 0.83;95%CI,0.74 至 0.95)。与非持续使用组相比,BP 假期组发生骨质疏松性骨折(HR 0.71;95%CI,0.65 至 0.79)、椎体骨折(HR 0.68;95%CI,0.59 至 0.78)和髋部骨折(HR 0.59;95%CI,0.50 至 0.70)的风险降低。女性在使用 BP 药物≥3 年后,无论出于何种原因,停止使用 BP 药物≥12 个月,与持续使用 BP 的患者相比,发生与骨质疏松相关的脆性骨折、髋部或椎体骨折的风险似乎没有增加。在我们的队列中,BP 假期仍然是一种可行的策略,可以平衡与长期使用 BP 相关的益处和潜在危害。